Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for IMC-P115C (PRAME-HLE-A02) in Solid tumor/s, Cancer. The expected timing is based on the latest available company guidance and may change.
12/23/24- First patient dosed. 2/26/25- Trial ongoing. 11/06/25:- Enrollment continues in Phase 1 dose escalation trial of IMC-P115C in multiple solid tumors. 02/25/26:- Phase 1 IMC-P115C solid tumor dose escalation trial enrolling; initial data expected H2 2026. 05/06/26:- IMC-P115C solid tumor Phase 1 dose escalation trial enrolling; company expects Phase 1 data in H2 2026. 08/06/26:- IMC-P115C Phase 1 solid tumor trial enrolling; data presentation expected H2 2026.
Verification
Confirm timing and program details against the company announcement or filing.